AlzeCure Pharma receives patent for anti-Alzheimer's drug

Published: 22-May-2023

ACD856 and other substances in the NeuroRestore platform stimulate several important signalling systems and signalling molecules in the brain

AlzeCure Pharma, a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's disease and pain, announced that the European Patent Office (EPO) has granted a patent covering the company’s candidate drug ACD856, which is developed against Alzheimer's disease and other disorders with cognitive impairment.

"This is another key step for ACD856, given that we have previously also been granted a US patent for this substance. This further builds on our patent portfolio for our NeuroRestore program," said Gunnar Nordvall, Head of Chemistry and IP at AlzeCure Pharma.

The company's patent application for ACD856 in Europe has been granted by the EPO and validated in 33 territories across Europe, including Germany, France, United Kingdom, Spain, Italy and Sweden. ACD856, the leading candidate drug in the NeuroRestore platform, is being developed against Alzheimer's disease. The patent number is 3 759 088 and the patent is expected to provide protection until 2039.

This is an important milestone for both the project and the company

"This is an important milestone for both the project and the company and further strengthens our commercial opportunities for ACD856," said AlzeCure’s CEO Martin Jönsson.

ACD856 and other substances in the NeuroRestore platform stimulate several important signalling systems and signalling molecules in the brain such as BDNF (Brain Derived Neurotrophic Factor) and NGF (Nerve Growth Factor), which can lead to improved cognition. Previous preclinical studies have shown that AlzeCure's drug candidates strengthen communication between nerve cells and improve cognitive ability, including learning and memory functions.

The candidate drug recently completed phase I clinical trials where both good safety and tolerability were observed in humans, and ACD856 crossed the blood-brain barrier and activated regions of the brain central to both cognition and depression treatment. New preclinical results also show potential neuroprotective and disease-modifying effects with these substances.

Trending Articles

You may also like